Clinical Trial

A Study of Real-World Characteristics, Treatment Patterns, and Clinical Outcomes in Patients With Metastatic Castration-Resistant Prostate Cancer

Not Yet Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this study is to assess treatment patterns, clinical outcomes, and patient characteristics among adults with metastatic castration-resistant prostate cancer (mCRPC) in the United States (US) real-world clinical practice. This study will be conducted using data extracted from the PRECISION (PRostatE Cancer dISease observatION) data platform.
Trial Details
NCT Number NCT07677254
Lead Sponsor Novartis Pharmaceuticals
Conditions Prostatic Neoplasms, Castration-Resistant
Enrollment 17,111 participants
Start Date 2026-06-30
Primary Completion 2026-11-30 (estimated)
Study Completion 2026-11-30 (estimated)
Updated on ClinicalTrials.gov 2026-06-30